- cafead Apr 15, 2021 at 10:12: AM
via AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching with a $63 million series A funding round.
"We put aside our oncology product to be able to 100% focus on this first in class and novel molecule we have," said CEO Judy Chou, Ph.D., speaking of the immune checkpoint agonist antibody neihulizumab.
article source
"We put aside our oncology product to be able to 100% focus on this first in class and novel molecule we have," said CEO Judy Chou, Ph.D., speaking of the immune checkpoint agonist antibody neihulizumab.
article source